Objective To investigate the clinical effect of programmed death-1(PD-1)inhibitor(Camrelizumab)immunotherapy combined with systemic chemotherapy in the treatment of recurrent and metastatic cervical cancer.Methods A total of 64 patients with recurrent and metastatic cervical cancer treated in People's Hospital of Dingzhou City from February 2019 to June 2021 were selected,and divided into the research group(n =32)and the control group(n =32)according to random number table method.The control group received systemic chemotherapy with Paclitaxel combined with Cisplatin,and the research group received systemic chemotherapy plus PD-1 inhibitor(Camrelizumab)immunotherapy.The clinical efficacy of the two groups was compared,and changes in the levels of squamous cell carcinoma(SCC)antigen,peripheral blood lym-phocytes/monocytes(LMR),platelets/lymphocytes(PLR)indexes and Kamofsky score were analyzed before treatment and after 3 cycles of treatment.The occurrence of toxic effects during treatment and the overall survival during follow-up were ob-served.Results The total effective rate and disease control rate of the research group[93.75%(30/32),96.88%(31/32)]were higher than those of the control group[68.75%(22/32),75.00%(24/32)],suggesting significant differences(P＜0.05).After 3 cycles of treatment,serum SCC and PLR levels in the two groups were lower than those before treatment,and LMR levels were higher than those before treatment;the improvement degree of the research group was better than that of the control group(P＜0.05).After treatment,the Kamofsky score of the two groups was higher than that before treatment,and higher in the research group than in the control group(P＜0.05).After treatment,the 1-year and 2-year survival rate and overall survival of the research group were higher or longer than those of the control group(P＜0.05).Most of the toxic effects in the two groups were grade 1 to 2.The proportion of platelet decrease and aminotransferase increase in the research group was 37.50%(12/32)and 28.12%(9/32),which was higher than that in the control group[18.75%(6/32)and 9.38%(3/32)](P＜0.05).There was no significant difference in the incidence of toxic effects such as anemia,leukope-nia,nausea,diarrhea and fatigue between the two groups(P＞0.05).In the research group,patients with reactive capillary hyperplasia,hypothyroidism,rash,shingles,and allergy disappeared after symptomatic treatment.Conclusion PD-1 inhibi-tor combined with systemic chemotherapy in the treatment of recurrent and metastatic cervical cancer can improve the clinical effect,quality of life and survival rate,prolong the survival period,improve the inflammatory and immune response state of the body,with fewer toxic effects and good tolerance in patients.
万方数据